Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987

Joaquim Bellmunt, Hans von der Maase, Graham M Mead, Iwona Skoneczna, Maria De Santis, Gedske Daugaard, Andreas Boehle, Christine Chevreau, Luis Paz-Ares, Leslie R Laufman, Eric Winquist, Derek Raghavan, Sandrine Marreaud, Sandra Collette, Richard Sylvester, Ronald de Wit

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

    368 Citationer (Scopus)

    Abstract

    The combination of gemcitabine plus cisplatin (GC) is a standard regimen in patients with locally advanced or metastatic urothelial cancer. A phase I/II study suggested that a three-drug regimen that included paclitaxel had greater antitumor activity and might improve survival.
    OriginalsprogEngelsk
    TidsskriftJournal of Clinical Oncology
    Vol/bind30
    Udgave nummer10
    Sider (fra-til)1107-13
    Antal sider7
    ISSN0732-183X
    DOI
    StatusUdgivet - 2012

    Citationsformater